Access to innovative cancer medicines in a middle-income country - the case of Mexico.
Daniela Moye-HolzRene Soria SaucedoJitse P van DijkSijmen A ReijneveldHans V HogerzeilPublished in: Journal of pharmaceutical policy and practice (2018)
The use and access of some essential innovative cancer medicines has increased over the years, but remains unequal across insurance schemes and regions. Particularly, the Ministry of Health Insurance scheme and Northern and Western regions in the country would benefit from additional efforts to increase access to essential cancer medicines.